EMA Authorised: Ibandronic Acid Teva (ibandronic acid) — Teva Pharma B.V.

View source ↗

Summary

EMA authorised Teva's ibandronic acid with indications including postmenopausal osteoporosis, breast neoplasms, neoplasm metastasis, and bone fractures.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Fractures Bone
• Neoplasm Metastasis
• Osteoporosis Postmenopausal

Drugs mentioned

• Ibandronic acid Teva (ibandronic acid)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms;Neoplasm Metastasis;Fractures, Bone;Osteoporosis, Postmenopausal. MAH: Teva Pharma B.V.. Decision date: 16/08/2024